ConMed not only beat Wall Street’s EPS estimates for 2024, they doubled reported EPS from $2.04 in 2023 to $4.25 for 2024. Can they keep the momentum going?
Starting with the fourth quarter ending December 2024, ConMed reported $345.9 million in sales and $52.5 million in operating profit which was also better than Wall Street expected, but in line with management’s guidance—which tells you how little credit Wall Street is giving CNMD these days.
Subscribe to continue reading
- Unlimited access to our content and archive
- Exclusive access to our newsletter
- Join the Conversation! Exclusive access to article comments.
